BRIEF-Bayer starts new Phase IIIb study with lung drug Riociguat

FRANKFURT, March 13 Thu Mar 13, 2014 3:32am EDT

FRANKFURT, March 13 (Reuters) - Bayer AG : * Says starts phase iiib study with riociguat in pah patients who had

insufficient response to pde-5 inhibitors

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.